Biomerieux 

$102.25
76
-$12.75-11.09% Monday 20:00

Statistics

Day High
115
Day Low
115
52W High
152
52W Low
102.25
Volume
868
Avg. Volume
52
Mkt Cap
12.1B
P/E Ratio
33.88
Dividend Yield
1.1%
Dividend
1.13

Upcoming

Dividends

1.1%Dividend Yield
Jun 25
$1.03
Jun 24
$0.91
Jun 23
$0.91
Jun 22
$0.91
Jun 21
$0.75
10Y Growth
11.53%
5Y Growth
8.38%
3Y Growth
7.45%
1Y Growth
9.61%

Earnings

27FebExpected
Q3 2023
Q4 2023
Q1 2024
Q2 2024
Q4 2024
Q2 2025
Q4 2025
0
0.73
1.46
2.19
Expected EPS
2.11719404169
Actual EPS
1.987975626

Financials

9.39%Profit Margin
Profitable
2020
2021
2022
2023
2024
2025
11.96BRevenue
1.12BNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow BMXMF. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Thermo Fisher Scientific
TMO
Mkt Cap214.25B
Thermo Fisher Scientific offers a broad range of analytical instruments and reagents, directly competing in the diagnostics and research sectors similar to Biomerieux.
Danaher
DHR
Mkt Cap152.13B
Danaher Corporation, through its subsidiaries like Cepheid, competes in the life sciences and diagnostics market, offering products that overlap with Biomerieux's offerings.
Bio-Rad Laboratories
BIO
Mkt Cap8.54B
Bio-Rad Laboratories provides a variety of products for the life science research and clinical diagnostics markets, making it a direct competitor in several areas of Biomerieux's business.
Resmed
RMD
Mkt Cap36.04B
ResMed Inc. is known for its products in the health sector, including diagnostics, where it competes with Biomerieux in certain niches.
Becton Dickinson
BDX
Mkt Cap51.22B
Becton, Dickinson and Company operates in the healthcare and diagnostics industries, offering products and services that compete with Biomerieux's diagnostics solutions.
Hologic
HOLX
Mkt Cap16.45B
Hologic, Inc. specializes in diagnostics and medical imaging systems, directly competing with Biomerieux in the diagnostics market.
Qiagen NV
QGEN
Mkt Cap10.16B
Qiagen N.V. offers technologies and products for preanalytical sample preparation and diagnostics, competing in the molecular diagnostics market alongside Biomerieux.
Abbott Laboratories
ABT
Mkt Cap214.96B
Abbott Laboratories has a broad range of healthcare products including diagnostics, competing with Biomerieux especially in the areas of infectious disease testing.
Agilent Technologies
A
Mkt Cap41.49B
Agilent Technologies provides analytical instruments, services, and consumables in the life sciences, diagnostics, and applied chemical markets, competing with Biomerieux in laboratory diagnostics.
Guardant Health
GH
Mkt Cap11.72B
Guardant Health operates in the precision oncology field, offering liquid biopsy tests that compete with Biomerieux's molecular diagnostics solutions in the oncology segment.

About

bioMérieux S.A. develops, manufactures, and markets in vitro diagnostic solutions for infectious diseases in France, Europe, Africa, the Middle East, North and South America, the Asia Pacific, and internationally. It operates through Clinical Applications and Industrial Applications segments. The company offers CHROMID RANGE, a chromogen culture media; air, surface, and water monitoring systems; BACT/ALERT VIRTUO, a blood sample culture system; BIOFIRE, a multiplex polymerase chain reaction system (PCR); BIOFIRE SPOTFIRE, a lowplex PCR point-of-care system; VITEK MS, a mass spectrometry system; VITEK 2, an automated identification and antimicrobial susceptibility testing (AST) system; API RANGE standardized ID strips; VITEK REVEAL, a rapid AST system; ETEST, a gradient method on culture media; BIOMERIEUX EPISEQ CS, a whole genome sequencing solution for epidemiologic monitoring; VIDAS, a specific marker of severe bacterial infections/sepsis; and Biomérieux vision suite, a software that provides information to support diagnosis and clinical decision making. It also provides culture media and associated instruments; ARGENE that provides PCR tests for diagnosing viral respiratory diseases; EMAG system and NUCLISENS extraction reagents for DNA and RNA extraction; GENE-UP and VERIFLOW for detection of microorganisms for the food industry; ETEST for manual measurement of minimum inhibitory concentration of an antibiotic; API and RAPIDEC CARBA NP for identification of bacteria and manual antimicrobial susceptibility testing; BIOBALL for quantitative microbiological quality control; CHEMUNEX, a microbiology instrument; ENDONEXT for detection of endotoxins; TEMPO for fluorescence counting of bacteria; and Hybiome, a CLIA technology, as well as lab consultancy service and training modules. The company was formerly known as B-D Mérieux. The company was founded in 1963 and is headquartered in Marcy-l'Étoile, France. bioMérieux S.A. is a subsidiary of Institut Mérieux SA.
Show more...
CEO
Mr. Pierre Boulud
Employees
14147
Country
FR
ISIN
FR0013280286

Listings

0 Comments

Share your thoughts

FAQ

What is Biomerieux stock price today?
The current price of BMXMF is $102.25 USD — it has decreased by -11.09% in the past 24 hours. Watch Biomerieux stock price performance more closely on the chart.
What is Biomerieux stock ticker?
Depending on the exchange, the stock ticker may vary. For instance, on exchange Biomerieux stocks are traded under the ticker BMXMF.
Is Biomerieux stock price growing?
BMXMF stock has risen by +0% compared to the previous week, the month change is a -14.93% fall, over the last year Biomerieux has showed a -18.85% decrease.
What is Biomerieux market cap?
Today Biomerieux has the market capitalization of 12.1B
When is the next Biomerieux earnings date?
Biomerieux is going to release the next earnings report on July 28, 2026.
What were Biomerieux earnings last quarter?
BMXMF earnings for the last quarter are 2.35 USD per share, whereas the estimation was 2.5 USD resulting in a -6.1% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Biomerieux revenue for the last year?
Biomerieux revenue for the last year amounts to 11.96B USD.
What is Biomerieux net income for the last year?
BMXMF net income for the last year is 1.12B USD.
Does Biomerieux pay dividends?
Yes, BMXMF dividends are paid annual. The last dividend per share was 1.03 USD. As of today, Dividend Yield (FWD)% is 1.1%.
How many employees does Biomerieux have?
As of April 02, 2026, the company has 14,147 employees.
In which sector is Biomerieux located?
Biomerieux operates in the Health Care sector.
When did Biomerieux complete a stock split?
The last stock split for Biomerieux was on September 21, 2017 with a ratio of 3:1.
Where is Biomerieux headquartered?
Biomerieux is headquartered in Marcy-l'Étoile, FR.